ZNTL
Zentalis Pharmaceuticals, Inc. NASDAQ Listed Apr 3, 2020$4.23
Mkt Cap $300.0M
52w Low $1.13
53.3% of range
52w High $6.95
50d MA $3.31
200d MA $2.15
P/E (TTM)
-2.1x
EV/EBITDA
-0.7x
P/B
1.4x
Debt/Equity
0.2x
ROE
-63.4%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
1.66
50d MA
$3.31
200d MA
$2.15
Avg Volume
1.9M
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
1359 Broadway · New York City, NY 10018 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.41 | -0.49 | -19.5% | 2.67 | -2.6% | -21.3% | +1.9% | +9.3% | +9.8% | +2.3% | — |
| Nov 10, 2025 | AMC | -0.49 | -0.37 | +24.5% | 1.32 | -5.3% | +6.1% | -4.3% | -1.5% | +0.8% | -0.8% | — |
| Aug 6, 2025 | AMC | -0.56 | -0.37 | +33.9% | 1.38 | +0.7% | +5.1% | -0.7% | -2.8% | +0.7% | +5.7% | — |
| May 14, 2025 | AMC | -0.67 | -0.67 | +0.0% | 1.19 | +4.2% | +5.9% | +0.0% | -0.8% | +2.4% | -5.5% | — |
| Mar 26, 2025 | AMC | -0.75 | -0.66 | +12.0% | 1.76 | +5.7% | +1.7% | +1.1% | -12.2% | -12.6% | -2.2% | — |
| Nov 12, 2024 | AMC | -0.92 | -0.56 | +39.1% | 3.71 | +10.0% | +5.7% | +0.8% | -12.2% | -12.1% | -2.0% | — |
| Aug 9, 2024 | AMC | -0.83 | -1.24 | -49.4% | 3.00 | +11.0% | +0.7% | +0.3% | -4.3% | +10.3% | -2.2% | — |
| May 7, 2024 | AMC | -0.77 | 0.14 | +118.2% | 12.31 | +0.2% | +1.0% | +0.7% | +0.2% | -6.3% | -0.7% | — |
| Feb 27, 2024 | AMC | -0.92 | -0.83 | +9.8% | 14.71 | +3.6% | +5.3% | -3.7% | +2.5% | -5.0% | -1.8% | — |
| Nov 6, 2023 | AMC | -1.01 | -0.79 | +21.8% | 12.48 | -3.8% | -18.3% | -2.0% | -0.3% | -1.3% | +4.3% | — |
| Aug 9, 2023 | AMC | -1.06 | -1.85 | -74.5% | 25.58 | -1.7% | +4.5% | +1.2% | +4.4% | -2.2% | -4.8% | — |
| May 10, 2023 | AMC | -0.96 | -1.07 | -11.5% | 24.39 | -0.3% | +7.1% | +2.9% | +4.2% | -1.3% | -3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $4.42 | $4.52 | +2.3% | +49.5% | -15.9% | -6.5% | +3.1% | -6.3% |
| Mar 27 | Guggenheim | Maintains | Buy → Buy | — | $2.67 | $2.60 | -2.6% | -21.3% | +1.9% | +9.3% | +9.8% | +2.3% |
| Nov 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $1.40 | $1.38 | -1.4% | -4.3% | -1.5% | +0.8% | -0.8% | +3.0% |
| Aug 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.38 | $1.39 | +0.7% | +5.1% | -0.7% | -2.8% | +0.7% | +5.7% |
| May 15 | Wedbush | Maintains | Neutral → Neutral | — | $1.19 | $1.24 | +4.2% | +5.9% | +0.0% | -0.8% | +2.4% | -5.5% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.24 | +4.2% | +5.9% | +0.0% | -0.8% | +2.4% | -5.5% |
| Mar 28 | Wedbush | Maintains | Neutral → Neutral | — | $1.79 | $1.75 | -2.2% | +1.1% | -12.2% | -12.6% | -2.2% | -5.1% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.86 | +5.7% | +1.7% | +1.1% | -12.2% | -12.6% | -2.2% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.77 | $1.82 | +2.8% | +6.8% | -6.3% | +1.1% | +1.7% | +4.9% |
| Jan 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.89 | $1.91 | +1.1% | -12.2% | +4.8% | -3.4% | -3.0% | +31.3% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $1.77 | -26.2% | -21.2% | -12.2% | +4.8% | -3.4% | -3.0% |
| Jan 28 | UBS | Maintains | Neutral → Neutral | — | $2.40 | $2.36 | -1.7% | +0.0% | -21.2% | -12.2% | +4.8% | -3.4% |
| Nov 15 | Guggenheim | Maintains | Buy → Buy | — | $3.95 | $3.99 | +1.0% | -12.2% | -12.1% | -2.0% | +4.7% | +1.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.95 | $3.99 | +1.0% | -12.2% | -12.1% | -2.0% | +4.7% | +1.6% |
| Sep 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.24 | $4.96 | +53.1% | +13.6% | +11.4% | +1.5% | +4.8% | -3.2% |
| Aug 12 | Wedbush | Upgrade | Underperform → Neutral | — | $3.00 | $3.33 | +11.0% | +0.7% | +0.3% | -4.3% | +10.3% | -2.2% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.00 | $3.33 | +11.0% | +0.7% | +0.3% | -4.3% | +10.3% | -2.2% |
| Jun 20 | UBS | Downgrade | Buy → Neutral | — | $4.14 | $4.31 | +4.1% | +26.8% | -9.5% | -3.2% | -8.7% | -1.0% |
| Jun 18 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $8.39 | $6.29 | -25.0% | -50.7% | +26.8% | -9.5% | -3.2% | -8.7% |
| Jun 18 | Stifel | Maintains | Buy → Buy | — | $8.39 | $6.29 | -25.0% | -50.7% | +26.8% | -9.5% | -3.2% | -8.7% |
| Jun 18 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $8.39 | $6.29 | -25.0% | -50.7% | +26.8% | -9.5% | -3.2% | -8.7% |
| Jun 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.39 | $6.29 | -25.0% | -50.7% | +26.8% | -9.5% | -3.2% | -8.7% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.39 | $6.29 | -25.0% | -50.7% | +26.8% | -9.5% | -3.2% | -8.7% |
| May 8 | Stifel | Maintains | Buy → Buy | — | $12.31 | $12.34 | +0.2% | +1.0% | +0.7% | +0.2% | -6.3% | -0.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.31 | $12.34 | +0.2% | +1.0% | +0.7% | +0.2% | -6.3% | -0.7% |
| Feb 28 | Wedbush | Maintains | Neutral → Neutral | — | $14.71 | $15.24 | +3.6% | +5.3% | -3.7% | +2.5% | -5.0% | -1.8% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.71 | $15.24 | +3.6% | +5.3% | -3.7% | +2.5% | -5.0% | -1.8% |
| Nov 8 | Wedbush | Downgrade | Outperform → Neutral | — | $10.20 | $10.03 | -1.7% | -2.0% | -0.3% | -1.3% | +4.3% | +14.4% |
| Nov 7 | Stifel | Maintains | Buy → Buy | — | $12.48 | $12.00 | -3.8% | -18.3% | -2.0% | -0.3% | -1.3% | +4.3% |
| Nov 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $12.48 | $12.00 | -3.8% | -18.3% | -2.0% | -0.3% | -1.3% | +4.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.48 | $12.00 | -3.8% | -18.3% | -2.0% | -0.3% | -1.3% | +4.3% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.58 | $25.15 | -1.7% | +4.5% | +1.2% | +4.4% | -2.2% | -4.8% |
| Aug 10 | Wedbush | Maintains | Outperform → Outperform | — | $25.58 | $25.15 | -1.7% | +4.5% | +1.2% | +4.4% | -2.2% | -4.8% |
| Aug 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $25.58 | $25.15 | -1.7% | +4.5% | +1.2% | +4.4% | -2.2% | -4.8% |
| Jun 7 | Wedbush | Maintains | Outperform → Outperform | — | $25.14 | $25.25 | +0.4% | -3.5% | -0.1% | -3.3% | +3.0% | +4.2% |
| Jun 7 | Stifel | Maintains | Buy → Buy | — | $25.14 | $25.25 | +0.4% | -3.5% | -0.1% | -3.3% | +3.0% | +4.2% |
| Jun 2 | Stifel | Maintains | Buy → Buy | — | $25.74 | $26.06 | +1.2% | +2.1% | -6.1% | +1.9% | -3.5% | -0.1% |
| May 29 | Stifel | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 26 | Wedbush | Maintains | Outperform → Outperform | — | $27.16 | $27.20 | +0.1% | +10.6% | -11.9% | -1.6% | -1.2% | +2.1% |
| May 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $27.16 | $27.20 | +0.1% | +10.6% | -11.9% | -1.6% | -1.2% | +2.1% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.16 | $27.20 | +0.1% | +10.6% | -11.9% | -1.6% | -1.2% | +2.1% |
| May 23 | Stifel | Maintains | Buy → Buy | — | $27.30 | $27.44 | +0.5% | -2.1% | -0.5% | +2.1% | +10.6% | -11.9% |
| May 19 | Jefferies | Maintains | Buy → Buy | — | $26.69 | $26.94 | +0.9% | -1.3% | +3.6% | -2.1% | -0.5% | +2.1% |
| May 15 | Stifel | Maintains | Buy → Buy | — | $26.89 | $27.06 | +0.6% | +4.2% | -1.3% | -3.8% | +0.3% | -1.3% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.39 | $24.32 | -0.3% | +7.1% | +2.9% | +4.2% | -1.3% | -3.8% |
| May 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.39 | $24.32 | -0.3% | +7.1% | +2.9% | +4.2% | -1.3% | -3.8% |
| May 11 | Stifel | Maintains | Buy → Buy | — | $24.39 | $24.32 | -0.3% | +7.1% | +2.9% | +4.2% | -1.3% | -3.8% |
| Mar 15 | Stifel | Maintains | Buy → Buy | — | $17.45 | $16.98 | -2.7% | +4.7% | +3.6% | -0.5% | -2.0% | -0.4% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.87 | $19.10 | +1.2% | +1.5% | +1.8% | -5.0% | +0.4% | -0.3% |
| Mar 1 | Stifel | Maintains | Buy → Buy | — | $18.93 | $18.98 | +0.3% | -0.3% | +1.5% | +1.8% | -5.0% | +0.4% |
No insider trades available.
8-K · 8.01
!! High
Zentalis Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Zentalis Pharmaceuticals advanced its azenosertib program by enrolling the first patient in the Phase 3 ASPENOVA trial for Cyclin E1-positive platinum-resistant ovarian cancer, potentially supporting full regulatory approval.
May 5
8-K · 7.01
! Medium
Zentalis Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Zentalis Pharmaceuticals presented clinical data and posters at the 2026 AACR Annual Meeting, potentially impacting investor perception of its oncology pipeline progress.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Zentel is advancing azenosertib into a confirmatory Phase 3 trial for Cyclin E1-positive PROC with optimized dosing, signaling meaningful clinical progress that could strengthen its pipeline and support future commercialization prospects.
Apr 9
8-K
Unknown — 8-K Filing
Zai Lab's completion of DENALI Part 2a enrollment positions azenosertib for critical dose-confirmation data in H1 2026, potentially accelerating its path toward regulatory approval and commercial viability for ovarian cancer treatment.
Mar 26
Data updated apr 27, 2026 11:47am
· Source: massive.com